A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
2期
提前终止
NCT04916002
| 适应症 | Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Triple Negative Breast Cancer |
|---|
| 分期 | 2期 |
|---|
| 申办方 | Regeneron Pharmaceuticals |
|---|
| 状态 | 提前终止 |
|---|
| 受试者人数 | 77 人 |
|---|
| 干预（药物） | vidutolimod, cemiplimab |
|---|
| 开始日期 | 2021年11月30日 |
|---|
| 完成日期 | 2024年10月31日 |
|---|
| 结果公布日 | 2025年12月5日 |
|---|
摘要
The goal of this study is to learn if giving cemiplimab and vidutolimod together could be effective in treating advanced cancer. The main questions it aims to answer are: * How many participants' cancers respond to vidutolimod together with cemiplimab? * Is vidutolimod together with cemiplimab safe and well-tolerated? * How well does vidutolimod together with cemiplimab treat participants' cancer? Participants will receive trial treatment for up to 2 years. 30 days after stopping treatment, participants will have a follow-up visit. After that visit, the trial staff will continue to follow up with participants about every 3 months, until the trial ends.
Objective Response Rate (ORR)
Up to 31.5 Months · Percentage of participants
| Cohort A1: CMP-001+Cemiplimab for CSCC | 44.0 Percentage of participants |
|---|
| Cohort A2: CMP-001+Cemiplimab for CSCC | 5.3 Percentage of participants |
|---|
| Cohort B1: CMP-001+Cemiplimab for MCC | 46.2 Percentage of participants |
|---|
| Cohort B2: CMP-001+Cemiplimab for MCC | 6.3 Percentage of participants |
|---|
| Cohort D: CMP-001+Cemiplimab for BCC | 25.0 Percentage of participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。